Drugs / Fluoroethylnormemantine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05921929 | May 2024 | Alzheimer disease, major depressive disorder, post-traumatic stress disorder | ReST Therapeutics | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fluoroethylnormemantine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05921929 ↗ |
| Known as | FENM | “Fluoroethylnormemantine (FENM)” NCT05921929 ↗ |
| Action | Inhibit | “Novel NMDA Receptor Antagonist” NCT05921929 ↗ |
| Route | Oral | “Participants will receive one single oral dose of FENM” NCT05921929 ↗ |